Abstract:

Objective To observe the outcome of travoprost for uncontrolled intraocular pressure after antiglaucomatous surgery in patients with primary angle closure glaucoma (PACG). Design Prospective case series. Participants The PACG patients with uncontrolled-intraocular pressure after laser periphery iridotomy (5 eyes of 5 cases) and trabeculectomy (30 eyes of 26 cases) were consecutively recruited in First Hospital of Shijiazhuang City, whose 60°anterior chamber angle at least was kept in opening. Methods All patients were intervened with 0.004% travoprost once daily. The changes in intraocular pressure were monitored with Goldmann applanation  tonometer before and after management for 2 weeks, 8 weeks and 12 weeks. Mean Outcome Measures Intraocular pressure and side actions of the drug. Results The average intraocular pressure was 24.58±5.12 mmHg before intervention with travoprost. After treating for 2 weeks, 8 weeks and 12 weeks, the average intraocular pressure was 18.48±3.12 mmHg, 17.12±4.05 mmHg, and 17.05±3.98 mmHg, respectively (P＜0.001). Systemic and local severe adverse reactions were not found in 12 weeks after administration. Conclusions This short-term observation of small samples showed that travoprost can effectively and safely reduce the uncontrollable intraocular pressure for patients with uncompletely anterior chamber angle closure of PACG after anti-glaucomatous operation. (Ophthalmol CHN, 2016, 25: 36-39)

Key words: Travoprost, primary angle closure glaucoma/medication